Breaking News

Merck, Ra To Develop Cyclomimetics

April 2, 2013

Extreme Diversity platform will help develop candidates

Ra Pharmaceuticals has entered into a collaboration with Merck for the development of Cyclomimetics, a new class of compounds that have the diversity and specificity of antibodies while retaining the attributes of small molecules. Ra will use its Extreme Diversity platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas.
Ra is eligible to receive as much as $200 million in payments, including upfront and research funding, as well as the achievement of discovery, development, regulatory and commercialization milestones for multiple targets.
“Cyclomimetics have novel properties that enable the targeting of protein-protein interactions, a property sought after for a wide range of disease indications,” said Doug Treco, Ph.D., co-founder, president and chief executive officer, Ra Pharmaceuticals. “The collaboration with Merck highlights the broad potential of our Extreme Diversity platform and provides us with the resources to strengthen and advance our core technology.”
“This agreement with Ra Pharmaceuticals underscores our strategy of collaborating with scientists who have developed innovative new technologies with the potential to complement and enhance our original research and product portfolio,” said Richard Tillyer, Ph.D., head of Drug Discovery and Preclinical Sciences, Merck Research Laboratories.

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems